Literature DB >> 27777062

Effectiveness, efficiency and efficacy in the multidimensional treatment of schizophrenia: Rethinking project.

Benedicto Crespo-Facorro1, Miguel Bernardo2, Josep Maria Argimon3, Manuel Arrojo4, Maria Fe Bravo-Ortiz5, Ana Cabrera-Cifuentes6, Julián Carretero-Román7, Manuel A Franco-Martín8, Paz García-Portilla9, Josep Maria Haro10, José Manuel Olivares11, Rafael Penadés12, Javier Del Pino-Montes13, Julio Sanjuán14, Celso Arango15.   

Abstract

Schizophrenia is a clinically heterogeneous syndrome affecting multiple dimensions of patients' life. Therefore, its treatment might require a multidimensional approach that should take into account the efficacy (the ability of an intervention to get the desired result under ideal conditions), the effectiveness (the degree to which the intended effect is obtained under routine clinical practice conditions or settings) and the efficiency (value of the intervention as relative to its cost to the individual or society) of any therapeutic intervention. In a first step of the process, a group of 90 national experts from different areas of health-care and with a multidimensional and multidisciplinary perspective of the disease, defined the concepts of efficacy, effectiveness and efficiency of established therapeutic interventions within 7 key dimensions of the illness: symptomatology; comorbidity; relapse and adherence; insight and subjective experience; cognition; quality of life, autonomy and functional capacity; and social inclusion and associated factors. The main conclusions and recommendations of this stage of the work are presented herein.
Copyright © 2016 SEP y SEPB. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Adherence; Adherencia; Antipsicóticos; Antipsychotics; Conciencia de enfermedad; Insight; Negative symptoms; Psychosis; Síntomas negativos

Mesh:

Substances:

Year:  2016        PMID: 27777062     DOI: 10.1016/j.rpsm.2016.09.001

Source DB:  PubMed          Journal:  Rev Psiquiatr Salud Ment        ISSN: 1888-9891            Impact factor:   3.318


  6 in total

1.  The Efficacy of Animal-Assisted Therapy in Patients with Dual Diagnosis: Schizophrenia and Addiction.

Authors:  Miguel Monfort; Ana Benito; Gonzalo Haro; Alejandro Fuertes-Saiz; Monserrat Cañabate; Abel Baquero
Journal:  Int J Environ Res Public Health       Date:  2022-05-30       Impact factor: 4.614

2.  Functional recovery in patients with schizophrenia: recommendations from a panel of experts.

Authors:  Guillermo Lahera; José L Gálvez; Pedro Sánchez; Miguel Martínez-Roig; J V Pérez-Fuster; Paz García-Portilla; Berta Herrera; Miquel Roca
Journal:  BMC Psychiatry       Date:  2018-06-05       Impact factor: 3.630

Review 3.  A Review of Clinical and Economic Evaluations Applied to Psychotropic Therapies Used in the Treatment of Schizophrenia in Argentina.

Authors:  Gisela Paula González; Nebel Silvana Moscoso; Fernando Pablo Lago
Journal:  Pharmacoecon Open       Date:  2018-09

4.  Analysis of the management of antipsychotics in a group of prisons.

Authors:  G Hervás; C Ruano; G Sanz-Alfayate; I Algora; M A Celdran; M A Mur
Journal:  Rev Esp Sanid Penit       Date:  2019

5.  Views of Schizophrenia Among Future Healthcare Professionals: Differences in Relation to Diagnostic Labelling, Causal Explanations, and Type of Academic Degree Program.

Authors:  Lucia Sideli; Crocettarachele Sartorio; Laura Ferraro; Giuseppe Mannino; Serena Giunta; Francesca Giannone; Fabio Seminerio; M Valentina Barone; Giuseppe Maniaci; Simonetta Montana; Fulvio Marchese; Daniele La Barbera; Caterina La Cascia
Journal:  Clin Neuropsychiatry       Date:  2021-10

6.  Clinical Validity of Subjective Clinical Prognosis in First Episode Psychosis Schizophrenia Patients: An Analysis of Data from the European First Episode Schizophrenia Trial (EUFEST) Study.

Authors:  Valentin Petre Matei; Alexandra Ioana Mihăilescu; Iuliana Raluca Gheorghe; Ruxandra Grigoraş; Andrei Crasan; Alina Roșca; Ovidiu Popa-Velea
Journal:  Neuropsychiatr Dis Treat       Date:  2020-05-18       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.